In a cohort of esophageal cancer patients treated with anti-PD-1/PD-L1 monotherapy, patients with higher baseline sPD-L1 levels displayed a remarkably increased disease control rate versus that of the lower subgroup [90]. Here, SPDL1 is linked to esophageal cancer.